HOME >> MEDICINE >> NEWS
Study Pinpoints Effectiveness Of Prostate Cancer Therapies To Patient Populations

Outcomes Measured In Relation To Radical Prostectomy, External Beam Radiation, And Seen Implant Therapy

Philadelphia, PA--Implanting radioactive-filled seeds into a cancerous prostate gland has been a largely sucessful method of treating the second-leading cancer killer among men for more than two decades. However, a new study says that, after an estimated 41-month follow-up, patients classified as high-risk had a poorer outcome after being treated with the seed implant therapy compared to those who underwent either radical prostectomy or external beam radiation. These findings are published in the September 16, 1998 issue of the Journal of the American Medical Association (JAMA). The study also concluded that no significant difference in outcome was noted in low risk patients across all treatment modalities for this short and limited follow-up period.

"These results suggest that a particular population of patients -- those we can pre-therapeutically determine to be "high risk" -- don't do as well with the seed therapy as judged by prostate specific antigen (PSA) levels, as with alternative forms of therapy," says Alan Wein, MD, senior investigator on the study and chief of urology at the University of Pennsylvania Cancer Center.

Penn researchers used collected data from 1,872 men who were treated for their localized prostate cancer between 1989 and 1997. The men underwent one of three treatment options: radical prostectomy, external beam radiation, or seed implant therapy offered at two clinical sites.

The researchers set out to measure the rate of disease-free survival for these patients. In doing so, they used three tests: PSA, biopsy Gleason score, and the American Joint Commission on Cancer staging (AJCC) T-stage.

As background, PSA blood tests measure the level of prstate-specific antigens in the blood: the results are reported as nanograms per milli
'"/>

Contact: Sue Montgomery
smontgom@mail.med.upenn.edu
(215) 349-5657
University of Pennsylvania School of Medicine
16-Sep-1998


Page: 1 2

Related medicine news :

1. Study of energy and health in Africa focuses spotlight on charcoal and forest management
2. Study shows promise in identifying kidney failure
3. Study shows patch therapy may be as effective as oral medications
4. Study shows soy is well accepted in school lunches
5. Study finds that coordinating care of chronically ill patients does not increase liability
6. Study provides new estimates of the causes of child mortality worldwide
7. Study finds factors linked to substance use disorder relapse among health care professionals
8. Study finds majority of women willing to accept cervical cancer vaccine for self and children
9. Study shows use of budesonide reduced the risk of asthma related events by 40% in children
10. Study shows risk of cardiac death after radiation for breast cancer has dramatically decreased
11. Study shows acrylamide in baked and fried food does not increase risk of breast cancer in women

Post Your Comments:
(Date:12/15/2014)... HealthDay Reporter FRIDAY, Dec. ... reassure the millions of American women who have migraine: The ... "There is no association between migraine and breast cancer risk," ... at Harvard Medical School. "There is no positive association, so ... protective effect either." About 18 percent of American women ...
(Date:12/15/2014)... The increase in prevalence of disabling hearing loss in the ... contributing to the growth in the global audiological market. Devices ... loss and balance disorders are known as audiological devices. An ... amplifier. The global market is expected to grow at a ... 2014 to 2019. Some of the factors which are driving ...
(Date:12/15/2014)... Austin, TX (PRWEB) December 15, 2014 ... with offices in 26 countries in North and South ... begun accepting responses from industry participants for its 2015 ... survey in order to identify upcoming business and market ... industry respondents. , The survey targets areas including:, ...
(Date:12/15/2014)... CA (PRWEB) December 15, 2014 At ... the organizations AutismOne and Focus Autism ... enlighten attendees with research on the effects of toxins ... testing and intervention information. , Luminaries such as ... researchers from abroad with esteemed, credentialed colleagues of the ...
(Date:12/15/2014)... December 15, 2014 Kenmode Precision Metal ... firm as Director of Quality Assurance. He brings ... systems, processes and certifications for manufacturers in the U.S. ... of Corporate Quality Manager at Sonoco Products Company in ... NetCom, Inc., and Quality Assurance Manager for Prince Industries, ...
Breaking Medicine News(10 mins):Health News: No Link Between Migraine, Breast Cancer Risk, Study Says 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 4Health News:Emergo’s Annual Survey Assessing the State of the Medical Device Industry Now Open 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3Health News:Kenmode Precision Metal Stamping Appoints Abid Rashid as Director of Quality Assurance 2
(Date:12/13/2014)... China , Dec 12, 2014 Mindray ... a leading developer, manufacturer and marketer of medical devices ... general meeting of shareholders held in Hong ... At the meeting, Mindray shareholders voted to re-elect incumbent ... a three-year term. Mindray,s shareholders did not re-elect ...
(Date:12/13/2014)... and INDIANAPOLIS , Dec. 12, ... and Chip Ganassi Racing Teams (CGRT), today announced a multi-year ... the primary sponsor of the No. 83 Novo Nordisk Chip ... the Verizon IndyCar Series. Kimball, 29, from ... only licensed driver with diabetes in the history of INDYCAR ...
(Date:12/13/2014)... 2014 Research and Markets ( ... "China Chemical Pharmaceutical Industry Report, 2013-2016"  report ... http://photos.prnewswire.com/prnh/20130307/600769 Chemical ... active pharmaceutical ingredient (API), and the gross margin ... than that of the API over the same ...
Breaking Medicine Technology:Mindray Announced Shareholder Resolutions Post 2014 Annual General Meeting 2Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 2Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 3Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 4Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 5Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 6Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 7China Chemical Pharmaceutical Industry Report, 2013-2016 2China Chemical Pharmaceutical Industry Report, 2013-2016 3
Cached News: